Pharma Rep Focus

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag opdivo

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. s Keytruda (pembrolizumab) and Bristol Myers Squibb’s Opdivo (nivolumab), based on the high volume of RSAs arranged for these drugs. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

Marketing

Marketing Medicine Leads Safety

Risk sharing agreements soar as market access risk increases

Pharmaceutical Technology

MARCH 17, 2023

She points out Merck’s Keytruda (pembrolizumab) and Bristol Myers Squibb’s Opdivo (nivolumab) as examples. In some cases, she said, “[drug] innovation would have been otherwise hindered by their price tag alone”. Click here to watch this webinar and access the presentation.

Marketing

Marketing Pharma Pharmaceutical Healthcare

Risk-sharing agreements are growing at a rate of 24%

Risk sharing agreements soar as market access risk increases

Stay Connected